Antonio Giordano, Breast Medical Oncologist at Dana-Farber Cancer Institute, shared a post by Erika Hamilton, Medical Oncologist and the Director of Breast Cancer Program at Sarah Cannon Research Institute, on X, adding:
“Important question: which 1L CDK4/6i to preserve efficacy of re-cycling cell cycle in 2L? What biomarkers can predict response to recycle cell cycle?”
Quoting Erika Hamilton’s post:
“Cristina Saura presents EMBER3 by prior CDK4/6.
Constant benefit among those with prior CDK, very important data in 2025 where most will get CDK in 1st line- 3.7 vs. 9.1 months.”
